Entera Bio Ltd. Share Based Compensation of Revenue

Share Based Compensation of Revenue of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Share Based Compensation of Revenue growth rates and interactive chart.


Highlights and Quick Summary

  • Share Based Compensation of Revenue for the quarter ending June 29, 2020 was 776.92% (a -12.52% decrease compared to previous quarter)
  • Year-over-year quarterly Share Based Compensation of Revenue increased by 32.43%
  • Annual Share Based Compensation of Revenue for 2019 was 628.39% (a 154.82% increase from previous year)
  • Annual Share Based Compensation of Revenue for 2018 was 246.6% (a Infinity% increase from previous year)
  • Twelve month Share Based Compensation of Revenue ending June 29, 2020 was 614.45% (a 29.9% increase compared to previous quarter)
  • Twelve month trailing Share Based Compensation of Revenue increased by Infinity% year-over-year
Trailing Share Based Compensation of Revenue for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
614.45% 473.02% 201.49% 0.0%
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Share Based Compensation of Revenue of Entera Bio Ltd.

Most recent Share Based Compensation of Revenueof ENTX including historical data for past 10 years.

Interactive Chart of Share Based Compensation of Revenue of Entera Bio Ltd.

Entera Bio Ltd. Share Based Compensation of Revenue for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 776.92% 888.1%
2019 435.29% 586.67% 197.3% 0.0% 628.39%
2018 60.0% 0.0% 0.0% 0.0% 246.6%
2017 0.0%

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.